102ND GENERAL ASSEMBLY
State of Illinois
2021 and 2022
HB3578
 
Introduced 2/22/2021, by Rep. Deb Conroy
 
SYNOPSIS AS INTRODUCED:
 

 
720 ILCS 570/315.7 new

     Amends the Illinois Controlled Substances Act. Provides that a prescriber shall prescribe naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient if the patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant. Provides other requirements and exemptions. Makes other changes. Effective January 1, 2022.
  


LRB102 12604 KMF 17942 b

 
 
A BILL FOR
 

  
HB3578LRB102 12604 KMF 17942 b


  
1    AN ACT concerning criminal law.
  
 
2    Be it enacted by the People of the State of Illinois,
 
3represented in the General Assembly:
  
 
 
4    Section 5. The Illinois Controlled Substances Act is 
5amended  by adding Section 315.7 as follows:
 
6    (720 ILCS 570/315.7 new)
7    Sec. 315.7. Prescriber requirements.
8    (a) Notwithstanding any provision of law to the contrary, 
9a prescriber shall: 
10        (1) Prescribe naloxone hydrochloride or another drug 
11    approved by the United States Food and Drug Administration 
12    for the complete or partial reversal of opioid depression 
13    to a patient when the patient presents with an increased 
14    risk for overdose, including a patient with a history of 
15    overdose, a patient with a history of substance use 
16    disorder, or a patient at risk for returning to a high dose 
17    of opioid medication to which the patient is no longer 
18    tolerant.
19        (2) Consistent with the existing standard of care, 
20    provide education to patients receiving a prescription 
21    under paragraph (1) of this subsection (a) on overdose 
22    prevention and the use of naloxone hydrochloride or 
23    another drug approved by the United States Food and Drug 
 
 
HB3578- 2 -LRB102 12604 KMF 17942 b

1    Administration for the complete or partial reversal of 
2    opioid depression. 
3        (3) Consistent with the existing standard of care, 
4    provide education on overdose prevention and the use of 
5    naloxone hydrochloride or another drug approved by the 
6    United States Food and Drug Administration for the 
7    complete or partial reversal of opioid depression to one 
8    or more persons designated by the patient, or, for a 
9    patient who is a minor, to the minor's parent or guardian. 
10    (b) This Section does not apply to a  prescriber when 
11prescribing to an inmate or youth under the jurisdiction of 
12the Department of Corrections or the Department of Juvenile 
13Justice. 
14    (c) A prescriber who does not comply with subsection (a) 
15is subject to administrative sanctions under the appropriate 
16licensing board. This Section does not create a private right 
17of action against a prescriber and does not limit a 
18prescriber's liability for the negligent failure to diagnose 
19or treat a patient. 
 
 
20    Section 99. Effective date. This Act takes effect January 
211, 2022.